BIOGEN INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BIOGEN INC. (BIIB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $88.10 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-04-29
- BIOGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $88.10M, a 4.76% increase year-over-year.
- BIOGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $78.40M, a 4.53% increase year-over-year.
- BIOGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $78.10M, a 7.13% increase year-over-year.
- BIOGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $84.10M, a 10.51% increase year-over-year.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month |
|---|---|---|---|
| 2026-03-31 | $88.10M 10-Q · filed 2026-04-29 | ||
| 2025-09-30 | $78.40M 10-Q · filed 2025-10-30 | $156.50M derived: sum of 2 quarters · filed 2025-10-30 | $240.60M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $78.10M 10-Q · filed 2025-07-31 | $162.20M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $84.10M 10-Q · filed 2026-04-29 | ||
| 2024-09-30 | $75.00M 10-Q · filed 2025-10-30 | $147.90M derived: sum of 2 quarters · filed 2025-10-30 | $224.00M derived: sum of 3 quarters · filed 2025-10-30 |
| 2024-06-30 | $72.90M 10-Q · filed 2025-07-31 | $149.00M derived: sum of 2 quarters · filed 2025-07-31 | |
| 2024-03-31 | $76.10M 10-Q · filed 2025-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |